基本信息
浏览量:116
职业迁徙
个人简介
Research Interest:
Nanomedicine Research Group :
Our research efforts are directed towards gaining an understanding of membrane structure and function at the molecular level and using the information gained to therapeutic advantage. Particular interests concern investigations on the functional roles of lipids in membranes employing model membrane systems and the generation and use of appropriately engineered liposomal nanoparticulate (LN) systems to deliver conventional and genetic drugs. Our interests in LN systems can be divided into three parts:
LN Delivery of siRNA :
RNA interference is a very attractive strategy for the treatment of human disease; however the therapeutic applicability of siRNAs has been hampered by the ineffective intracellular delivery of functional siRNAs to target cells in vivo. A focus of our laboratory is the design of LN systems that are able to effectively deliver their contents intracellularly following systemic administration, thus enabling the therapeutic use of siRNA. One important aspect of this work is the design and characterization of novel cationic lipids. The challenge in this work is to develop LN systems that are stable when in the circulation but are able to destabilize biological membranes following arrival at target tissue.
LN Delivery of Immunostimulatory Drugs :
In addition to passively accumulating at sites of inflammation and malignant disease, LN delivery systems are naturally taken up by cells of the immune system following systemic administration. For this reason, our research focuses on using LN to enhance the delivery of immunostimulatory oligodeoxynucleotides containing CpG motifs to antigen presenting cells. This work is aimed at stimulating the innate immune system to improve the potency of monoclonal antibodies in cancer therapy as well as developing more effective vaccine adjuvants for use against infectious and malignant disease.
LN Encapsulation of Conventional Chemotherapeutics :
The aim of our research with respect to the encapsulation of conventional chemotherapeutics is to take advantage of the natural tendency of long-circulating LN systems to accumulate at tumour sites. Our research in this area focuses on designing LN delivery systems which have optimized circulation lifetimes, to allow for an increased concentration of drug at the tumour site, and optimized drug release characteristics, to maximize the benefits of providing local sustained release of cell cycle-specific drugs at the site of disease. In addition, we are investigating ways in which to extend the LN technology to drugs that currently are not amenable to loading and retention in LN systems in attempt to increase the therapeutic index of already established drugs. A liposomal formulation of doxorubicin (the most commonly employed anticancer drug) developed in this laboratory is currently in advanced clinical trials in the United States.
Nanomedicine Research Group :
Our research efforts are directed towards gaining an understanding of membrane structure and function at the molecular level and using the information gained to therapeutic advantage. Particular interests concern investigations on the functional roles of lipids in membranes employing model membrane systems and the generation and use of appropriately engineered liposomal nanoparticulate (LN) systems to deliver conventional and genetic drugs. Our interests in LN systems can be divided into three parts:
LN Delivery of siRNA :
RNA interference is a very attractive strategy for the treatment of human disease; however the therapeutic applicability of siRNAs has been hampered by the ineffective intracellular delivery of functional siRNAs to target cells in vivo. A focus of our laboratory is the design of LN systems that are able to effectively deliver their contents intracellularly following systemic administration, thus enabling the therapeutic use of siRNA. One important aspect of this work is the design and characterization of novel cationic lipids. The challenge in this work is to develop LN systems that are stable when in the circulation but are able to destabilize biological membranes following arrival at target tissue.
LN Delivery of Immunostimulatory Drugs :
In addition to passively accumulating at sites of inflammation and malignant disease, LN delivery systems are naturally taken up by cells of the immune system following systemic administration. For this reason, our research focuses on using LN to enhance the delivery of immunostimulatory oligodeoxynucleotides containing CpG motifs to antigen presenting cells. This work is aimed at stimulating the innate immune system to improve the potency of monoclonal antibodies in cancer therapy as well as developing more effective vaccine adjuvants for use against infectious and malignant disease.
LN Encapsulation of Conventional Chemotherapeutics :
The aim of our research with respect to the encapsulation of conventional chemotherapeutics is to take advantage of the natural tendency of long-circulating LN systems to accumulate at tumour sites. Our research in this area focuses on designing LN delivery systems which have optimized circulation lifetimes, to allow for an increased concentration of drug at the tumour site, and optimized drug release characteristics, to maximize the benefits of providing local sustained release of cell cycle-specific drugs at the site of disease. In addition, we are investigating ways in which to extend the LN technology to drugs that currently are not amenable to loading and retention in LN systems in attempt to increase the therapeutic index of already established drugs. A liposomal formulation of doxorubicin (the most commonly employed anticancer drug) developed in this laboratory is currently in advanced clinical trials in the United States.
研究兴趣
论文共 503 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Proceedings of the National Academy of Sciences of the United States of Americano. 11 (2024)
BIOSENSORS & BIOELECTRONICS (2024)
Nature reviews Drug discoveryno. 9 (2024): 709-722
Francesca Ferraresso, Katherine Badior, Monica Seadler, Youjie Zhang, Amanda Wietrzny,Massimo F. Cau, Amber Haugen, Geoffrey G. Rodriguez, Mitchell R. Dyer,Pieter R. Cullis,Eric Jan,Christian J. Kastrup
MOLECULAR THERAPYno. 3 (2024)
Trends in Pharmacological Sciencesno. 5 (2024): 406-418
Mohammad A. Anwar,Ammar H. Keshteli, Haiyan Yang, Windy Wang, Xukun Li, Helen M. Messier,Pieter R. Cullis,Christoph H. Borchers,Robert Fraser,David S. Wishart
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGYno. 4 (2024): 182-192
Belal Tafech, Mohammad-Reza Rokhforouz,Jerry Leung, Molly M. H. Sung,Paulo J. C. Lin,Don D. Sin,Daniel Lauster,Stephan Block,Bradley S. Quon,Ying Tam,Pieter Cullis,James J. Feng,Sarah Hedtrich
Advanced healthcare materials/Advanced Healthcare Materials (2024)
Colton Strong,Jerry Leung, Emma Kang, Katherine E. Badior,Madelaine Robertson, Nicolas Pereyra,Elyn Rowe, Amanda Wietrzny, Brenda Ma, Zechariah Noronha, Deaglan Arnold, Marco A. Ciufolini,Dana V. Devine,Eric Jan,Pieter R. Cullis,Christian J. Kastrup
Blood (2024)
Massimo F. Cau,Francesca Ferraresso, Monica Seadler,Katherine Badior, Youjie Zhang, Laura M. Ketelboeter, Geoffrey Rodriguez, Taylor Chen, Matteo Ferraresso, Amanda Wietrzny,Madelaine Robertson, Amber Haugen,Pieter R. Cullis, Marc de Moya,Mitchell Dyer,Christian J. Kastrup
Molecular therapy Methods & clinical developmentpp.101258-101258, (2024)
Jerry Leung, Asel Primbetova,Colton Strong, Brenna N. Hay, Han Hsuan Hsu,Andrew Hagner,Leonard J. Foster,Dana Devine,Pieter R. Cullis,Peter W. Zandstra,Christian J. Kastrup
Journal of Thrombosis and Haemostasis (2024)
加载更多
作者统计
#Papers: 503
#Citation: 46443
H-Index: 113
G-Index: 203
Sociability: 7
Diversity: 0
Activity: 3
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn